TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28213170

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 154

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Combination therapy (Mirtazapine + SSRIs)
Number of subjects: 154

Group type: COMPARATOR
Intervention: SSRIs monotherapy
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Mirtazapine add-on for SSRIs non-responders
Number of subjects: 154

Group type: COMPARATOR
Intervention: SSRIs add-on for mirtazapine non-responders
Number of subjects: 154
Study: 25835002

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 117

Group type: COMPARATOR
Intervention: Verapamil SR
Number of subjects: 117
Study: 23602242

Group type: EXPERIMENTAL
Intervention: Higher glycemic load diet
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Higher grain intake
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: High dietary glycemic load (GL)
Number of subjects: 82
Study: 21496149

Group type: EXPERIMENTAL
Intervention: Continuous intravenous (IV) insulin infusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 61
Study: 19954075

Group type: EXPERIMENTAL
Intervention: Domestic split influenza virus vaccine (study group)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Imported vaccine (control group 1)
Number of subjects: 606

Group type: COMPARATOR
Intervention: Imported vaccine (control group 2)
Number of subjects: 606
Study: 16714146

Group type: EXPERIMENTAL
Intervention: Exercise trained group (n=17)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untrained control group (n=12)
Number of subjects: 29
Study: 14660311

Group type: EXPERIMENTAL
Intervention: Midazolam and topical lidocaine‐prilocaine cream (EMLA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ketamine and topical placebo cream
Number of subjects: 13
Study: 11600472

Group type: COMPARATOR
Intervention: Control or untreated arms of randomised controlled trials for primary prevention of variceal haemorrhage
Number of subjects: 1475
Study: 9211479

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.03 mg/ml, 20 microliters applied topically for 30 min)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Capsaicin-induced mechanical hyperalgesia
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Capsaicin-induced hyperalgesia
Number of subjects: 70
Study: 8484146

Group type: EXPERIMENTAL
Intervention: Intensive dynamic back exercises with hyperextension
Number of subjects: 62

Group type: COMPARATOR
Intervention: Intensive dynamic back exercises without hyperextension
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hyperextension group
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hyperextension exercises
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Training duration
Number of subjects: 62
Study: 3628610

Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg/70 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg/70 kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29713156

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg
Number of subjects: 2159
Study: 26566165

Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions at 60°·s
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions at 120°·s
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions at 180°·s
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions (all velocities)
Number of subjects: 12
Study: 23937643

Group type: EXPERIMENTAL
Intervention: High levels of global self-disclosure reported by perceivers who valued relationships with targets.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived high levels of self-disclosure when targets were responsive.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions of low self-disclosure predicted decreased perceptions of diagnosticity of targets' behavior.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental manipulations in Studies 5 and 6.
Number of subjects: 0
Study: 24082325

Group type: EXPERIMENTAL
Intervention: Yoga methods (pain-managing) for three months, eight 90-minute sessions per month
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study: 20716255

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 14 days
Number of subjects: 460

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily plus metronidazole 500 mg twice daily for 14 days
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 460

Group type: COMPARATOR
Intervention: Levofloxacin plus metronidazole
Number of subjects: 460
Study: 18259086

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Early onset of clinical improvement (first 2 weeks)
Number of subjects: 39
Study: 15804500

Group type: EXPERIMENTAL
Intervention: Myopic subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal-sighted subjects
Number of subjects: 0
Study: 12450492

Group type: EXPERIMENTAL
Intervention: Depth ordering consistent with perceptual occlusion of static elements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placing moving components behind static elements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induced surface stimulus configuration
Number of subjects: 0
Study: 10425379

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monte Carlo simulations
Number of subjects: 0
Study: 7538238

Group type: EXPERIMENTAL
Intervention: Transurethral resection (TURP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Incision of the prostate (TUIP)
Number of subjects: 120
Study: 2290163

Group type: EXPERIMENTAL
Intervention: Subacromial injection of triamcinolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral diclofenac 50 mg TDS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6937514

Group type: EXPERIMENTAL
Intervention: 0.1% SnF2 mouthrinse
Number of subjects: 400

Group type: COMPARATOR
Intervention: 0.05% NaF mouthrinse (active control)
Number of subjects: 400
Study: 31297583

Group type: EXPERIMENTAL
Intervention: ACL reconstruction with LEAT
Number of subjects: 125

Group type: COMPARATOR
Intervention: ACL reconstruction alone
Number of subjects: 125
Study: 30107904

Group type: COMPARATOR
Intervention: 1 to 7 drinks/week
Number of subjects: 6083

Group type: COMPARATOR
Intervention: 8 to 14 drinks/week
Number of subjects: 6083

Group type: COMPARATOR
Intervention: >14 drinks/week
Number of subjects: 6083
Study: 26784323

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque; n = 6)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Iohexol (Omnipaque; n = 6)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both Iodixanol and Iohexol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 12
Study: 25045936

Group type: EXPERIMENTAL
Intervention: Three whole eggs per day (EGG)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Yolk-free egg substitute (SUB)
Number of subjects: 37
Study: 22086300

Group type: EXPERIMENTAL
Intervention: 40 μg vitamin D(3) plus 1,000 mg calcium per day
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1,000 mg calcium per day (Control)
Number of subjects: 45
Study: 19292654

Group type: EXPERIMENTAL
Intervention: Bofu‐tsusho‐san (BTS) 7.5 g/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo of BTS 7.5 g/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Vitamin E 500 mg and Vitamin C 1000 mg/day
Number of subjects: 18
Study: 17485599

Group type: EXPERIMENTAL
Intervention: Low-sodium feeding (51.3 mmol per day)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: High-sodium feeding (307.8 mmol per day)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: High-sodium plus potassium supplementation (60 mmol per day)
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Low sodium
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: High sodium
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 1906
Study: 15170412

Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Outpatient exercise program
Number of subjects: 43
Study: 11594439

Group type: EXPERIMENTAL
Intervention: Enadoline (160 microg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydromorphone (1.5, 3, and 6 mg/70 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Butorphanol (1.5, 3, 6, and 12 mg/70 kg)
Number of subjects: 6
Study: 9659646

Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2/O2 monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonmonitored infants
Number of subjects: 0
Study: 7665644

Group type: EXPERIMENTAL
Intervention: Infectious mononucleosis (IM) patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fatal infectious mononucleosis (IM) patients
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EBVAHS patients (acute phase)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: EBVAHS patients (convalescent phase)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: CAEBV patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy control children
Number of subjects: 68
Study: 2527534

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Food
Number of subjects: 16
Study: 184377

Group type: EXPERIMENTAL
Intervention: N 041 (essential phospholipids in combination with Clofibrate)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clofibrate alone
Number of subjects: 96
Study: 30738219

Group type: EXPERIMENTAL
Intervention: One-day CBT Stress management programme (DISCOVER) with telephone follow-up
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 155
Study: 28352163

Group type: EXPERIMENTAL
Intervention: Exercise intervention (EG) - balance and strength training for 60 min, three times/week for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CG) - no modification of usual habits
Number of subjects: 65
Study: 25466509

Group type: EXPERIMENTAL
Intervention: FOLFIRI plus aflibercept
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1226
Study: 23021878

Group type: EXPERIMENTAL
Intervention: Omalizumab (4 to 8 subcutaneous doses, n = 16)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 24
Study: 21689393

Group type: EXPERIMENTAL
Intervention: Comprehensive early intervention services for 18 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study: 19624838

Group type: EXPERIMENTAL
Intervention: Cineole 200 mg, 3 times daily for 6 months
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 17114212

Group type: EXPERIMENTAL
Intervention: Occupational therapy (10 sessions over five weeks)
Number of subjects: 135
Study: 14989750

Group type: EXPERIMENTAL
Intervention: APC Clarity brackets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Uncoated Clarity brackets with Transbond XT
Number of subjects: 20
Study: 11788018

Group type: EXPERIMENTAL
Intervention: Immediate cystoscopy
Number of subjects: 288
Study: 9140801

Group type: EXPERIMENTAL
Intervention: moexipril 7.5 mg/HCTZ 12.5 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: metoprolol 100 mg/HCTZ 12.5 mg
Number of subjects: 140
Study: 7475401

Group type: EXPERIMENTAL
Intervention: Revealed parameters to some providers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not revealing parameters to other providers (Control)
Number of subjects: 0
Study: 2142246

Group type: EXPERIMENTAL
Intervention: 60 mg toremifene daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg toremifene daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRH functional test
Number of subjects: 0
Study: 6766049

Group type: EXPERIMENTAL
Intervention: Elemental diet by a needle catheter jejunostomy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intravenous control
Number of subjects: 26
Study: 30558968

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-impregnated gel dressing
Number of subjects: 115

Group type: COMPARATOR
Intervention: Transparent polyurethane dressing
Number of subjects: 115
Study: 27189071

Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) to the right cerebellar hemisphere
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not specified in the abstract)
Number of subjects: 14
Study: 26506580

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) delivered over 14 sessions for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition consisting of written psycho-education materials and weekly telephone monitoring
Number of subjects: 30
Study: 23399518

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 952

Group type: COMPARATOR
Intervention: Mail follow-up
Number of subjects: 952
Study: 21846154

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg (titrated to 300 mg after 6 weeks)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 19542517

Group type: EXPERIMENTAL
Intervention: 1SMS (one weekly SMS feedback)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 3SMS (three weekly SMS feedbacks)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control condition (without intervention)
Number of subjects: 174
Study: 17287682

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitated PCI (immediate planned PCI after i.v. thrombolytic therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescue PCI after failed thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rescue PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser thrombectomy before PCI
Number of subjects: 0
Study: 15169865

Group type: EXPERIMENTAL
Intervention: Cerebellar patients
Number of subjects: 26

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 26
Study: 11527067

Group type: EXPERIMENTAL
Intervention: Qi therapy (QT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study: 8840055

Group type: EXPERIMENTAL
Intervention: 100 mg esmolol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 200 mg esmolol
Number of subjects: 45

Group type: COMPARATOR
Intervention: 20 ml normal saline (Control Group P)
Number of subjects: 45
Study: 1299974

Group type: EXPERIMENTAL
Intervention: 5-FU as a short i.v. perfusion or as a continuous perfusion over 3 to 5 days
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: 5-FU as a continuous perfusion
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Retreatment with 5-FU
Number of subjects: 1097

Group type: EXPERIMENTAL
Intervention: Adverse cardiac effects
Number of subjects: 1097
Study: 6391417

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMGBF) plus physiotherapy (PT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy (PT) alone
Number of subjects: 0
Study: 31072566

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus aspirin
Number of subjects: 27395

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 27395

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg plus aspirin
Number of subjects: 27395
Study: 28825348

Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT) - 3 times/week for 20 minutes, including five 3-minute exercise intervals at 80% of peak oxygen uptake (VO2-peak)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control training (CT) - continuously 5 times/week for 30 minutes/session at 65% of VO2-peak
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-intensity training (HIT)
Number of subjects: 60
Study: 26831333

Group type: EXPERIMENTAL
Intervention: 1% linalool inhalation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Carrier oil (control)
Number of subjects: 37
Study: 25233668

Group type: EXPERIMENTAL
Intervention: Photoelectric combined with musical treatment (group A)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Acupuncture (group B)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo (starch tablet, group C)
Number of subjects: 126
Study: 22061429

Group type: EXPERIMENTAL
Intervention: Whole grain rye porridge breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Refined wheat bread breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both breakfasts
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 24
Study: 19095665

Group type: EXPERIMENTAL
Intervention: Cook catheter
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Frydman catheter
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Cook catheter (Operator 1)
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Cook catheter (Operator 2)
Number of subjects: 1155

Group type: EXPERIMENTAL
Intervention: Cook catheter (Operator 3)
Number of subjects: 1155
Study: 17925627

Group type: EXPERIMENTAL
Intervention: Sexual therapy group (n=47)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (n=45)
Number of subjects: 92
Study: 15756442

Group type: EXPERIMENTAL
Intervention: Irinotecan 125 mg/m2, FA 20 mg/m2 followed by 5‐FU 500 mg/m2 bolus, weekly for 4 weeks (arm A)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Irinotecan 350 mg/m2 alternating with FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day for 5 days (arm B)
Number of subjects: 149

Group type: COMPARATOR
Intervention: FA 20 mg/m2/day followed by 5‐FU bolus 425 mg/m2/day over 5 days every 4 weeks (arm C, Mayo Clinic regimen)
Number of subjects: 149
Study: 12077765

Group type: EXPERIMENTAL
Intervention: Serum MMP-2 levels in POBA patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Serum MMP-1 levels in POBA patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Serum TIMP-1 and TIMP-2 levels in POBA patients
Number of subjects: 36
Study: 10211526

Group type: EXPERIMENTAL
Intervention: Transanal inserted stapler
Number of subjects: 58

Group type: COMPARATOR
Intervention: Biofragmentable anastomotic ring
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study: 8559001

Group type: EXPERIMENTAL
Intervention: Fordtran solution (polyethylene glycol solution)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ringer's solution (whole-gut lavage)
Number of subjects: 100
Study: 2341994

Group type: EXPERIMENTAL
Intervention: Counselling programme (education and psychological support) in addition to routine care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care only (Control)
Number of subjects: 60
Study: 7018164

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose given to females with treated partners
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo given to females with untreated partners
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g single oral dose
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 137
Study: 31526071

Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (mock infiltration)
Number of subjects: 42
Study: 27768806

Group type: EXPERIMENTAL
Intervention: Media Smart
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Life Smart
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: HELPP
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Control (usual school class)
Number of subjects: 1316
Study: 25425651

Group type: EXPERIMENTAL
Intervention: Hypercapnic infants
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Fluctuators
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Max PaCO2 increase (per 10 mm Hg)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Max PaCO2
Number of subjects: 1316
Study: 25605211

Group type: EXPERIMENTAL
Intervention: Laparoscopic nerve-sparing radical hysterectomy (LNRH)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Classical laparoscopic radical hysterectomy (LRH)
Number of subjects: 65
Study: 23226223

Group type: EXPERIMENTAL
Intervention: PCI+OMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: OMT
Number of subjects: 0
Study: 19036903

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (260 mg/m² q3wk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: docetaxel (100 mg/m² q3wk)
Number of subjects: 24

Group type: COMPARATOR
Intervention: paclitaxel (175 mg/m² q3wk)
Number of subjects: 24
Study: 17279848

Group type: EXPERIMENTAL
Intervention: Higher power groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower power groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit and implicit measures of group attraction
Number of subjects: 0
Study: 15469651

Group type: EXPERIMENTAL
Intervention: DHA-rich oil (4.9 g DHA/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EPA-rich oil (4.8 g EPA/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 42
Study: 11781674

Group type: EXPERIMENTAL
Intervention: Vietnamese foods (three rices, three noodle products, three sweet foods)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference food (glucose sugar)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of GI values between racial groups
Number of subjects: 12
Study: 9757148

Group type: EXPERIMENTAL
Intervention: Supernatant fraction (naringin and 6',7'-dihydroxybergamottin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Particulate fraction
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 7821886

Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46